Skip to main content
Erschienen in: Drugs & Aging 8/2004

01.07.2004 | Review Article

Time Course of Response to Antidepressants in Late-Life Major Depression

Therapeutic Implications

verfasst von: Ellen M. Whyte, Dr Mary Amanda Dew, Ariel Gildengers, Eric J. Lenze, Ashok Bharucha, Benoit H. Mulsant, Charles F. Reynolds III

Erschienen in: Drugs & Aging | Ausgabe 8/2004

Einloggen, um Zugang zu erhalten

Abstract

In the treatment of depression, there is considerable interest in the time course of response and, in particular, the speed with which individuals recover from depressive episodes. Examination of the time course and speed of response is critical for assessing the usefulness of specific treatments. However, while this issue has received attention in mid-life adult populations, it has received little consideration in the context of late-life major depression. The synthesis of empirical reports indicates that, while older adults with depression seem to respond with the same speed as mid-life adults, several factors have consistently been associated with reduced speed of response to antidepressant treatment, including greater severity of depressive symptoms and co-occurring anxiety symptoms. Limited evidence suggests that sleep impairment and genetic factors (e.g. presence of the s allele of the serotonin transporter gene promoter region) may also be associated with reduced speed of response. Some factors have consistently been found to be unrelated to speed of response (demographic characteristics, nonpsychiatric physical illnesses) whereas other factors have only mixed evidence supporting any effect (psychosocial and other clinical factors). While there is little work available to date, some evidence suggests that time course and speed of response affect longer-term outcomes of depression pharmacotherapy; thus, older adults with more rapid versus slower patterns of response may differ in the types of maintenance treatment needed to avert additional depressive episodes.
None of potential strategies for accelerating speed of response have been clearly shown to be effective in late-life depression. Future treatment studies for late-life depression should routinely consider not only overall efficacy of a given pharmacotherapy (i.e. total rate of response), but time course and speed of response. To this end, new investigations must be designed to overcome the methodological limitations of prior studies that have examined time course and they should include a range of potential covariates and outcomes of between-patient differences in speed of response. Better understanding of factors related to such differences may suggest new intervention strategies to accelerate response.
Literatur
1.
Zurück zum Zitat Muller H, Moller HJ. Methodological problems in the estimation of the onset of the antidepressant effect. J Affect Disord 1998; 48: 15–23PubMedCrossRef Muller H, Moller HJ. Methodological problems in the estimation of the onset of the antidepressant effect. J Affect Disord 1998; 48: 15–23PubMedCrossRef
2.
Zurück zum Zitat Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001; 62(15 Suppl.): 18–21 Thase ME. Methodology to measure onset of action. J Clin Psychiatry 2001; 62(15 Suppl.): 18–21
3.
Zurück zum Zitat Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001; 18: 355–68PubMedCrossRef Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drugs Aging 2001; 18: 355–68PubMedCrossRef
4.
Zurück zum Zitat Reynolds III CF. Treatment of major depression in later life: a life cycle perspective. Psychiatr Q 1997; 68: 221–46PubMedCrossRef Reynolds III CF. Treatment of major depression in later life: a life cycle perspective. Psychiatr Q 1997; 68: 221–46PubMedCrossRef
5.
Zurück zum Zitat Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 2001; 62(4 Suppl.): 12–6PubMed Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 2001; 62(4 Suppl.): 12–6PubMed
6.
7.
Zurück zum Zitat Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 143: 382–9CrossRef Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 143: 382–9CrossRef
8.
Zurück zum Zitat Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, 1976; Publication ADM 76–338: 218–22 Guy W, editor. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, 1976; Publication ADM 76–338: 218–22
9.
Zurück zum Zitat Ackerman DL, Greenland S, Bystritsky A, et al. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000; 20: 658–65PubMedCrossRef Ackerman DL, Greenland S, Bystritsky A, et al. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000; 20: 658–65PubMedCrossRef
10.
Zurück zum Zitat Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157: 729–36PubMedCrossRef Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157: 729–36PubMedCrossRef
11.
Zurück zum Zitat Evans M, Hammond M, Wilson K, et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 1997; 12: 817–24PubMedCrossRef Evans M, Hammond M, Wilson K, et al. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 1997; 12: 817–24PubMedCrossRef
12.
Zurück zum Zitat Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs fluoxetine in patients aged 70 or over with major depression. Am J Geriatr Psychiatry 1999; 7: 221–7PubMedCrossRef Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs fluoxetine in patients aged 70 or over with major depression. Am J Geriatr Psychiatry 1999; 7: 221–7PubMedCrossRef
13.
Zurück zum Zitat Kyle CJ, Petersen HEH, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitryptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8: 147–53PubMedCrossRef Kyle CJ, Petersen HEH, Overo KF. Comparison of the tolerability and efficacy of citalopram and amitryptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8: 147–53PubMedCrossRef
14.
Zurück zum Zitat Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541–50PubMed Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10: 541–50PubMed
15.
Zurück zum Zitat Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13(2 Suppl.): 34–9S Schöne W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13(2 Suppl.): 34–9S
16.
Zurück zum Zitat Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002; 63: 694–9PubMedCrossRef Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002; 63: 694–9PubMedCrossRef
17.
Zurück zum Zitat Forlenza OV, Almeida OP, Stoppe A, et al. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001; 13: 75–84PubMedCrossRef Forlenza OV, Almeida OP, Stoppe A, et al. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001; 13: 75–84PubMedCrossRef
18.
Zurück zum Zitat Karlsson I, Godderis J, Augusto De Mendonca Lima C, et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with and without mild to moderate dementia. Int J Geriatr Psychiatry 2000; 15: 295–305PubMedCrossRef Karlsson I, Godderis J, Augusto De Mendonca Lima C, et al. A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with and without mild to moderate dementia. Int J Geriatr Psychiatry 2000; 15: 295–305PubMedCrossRef
19.
Zurück zum Zitat Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9: 406–14PubMed Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9: 406–14PubMed
20.
Zurück zum Zitat Navarro V, Gastó C, Torres X, et al. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001; 103: 435–40PubMedCrossRef Navarro V, Gastó C, Torres X, et al. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001; 103: 435–40PubMedCrossRef
21.
Zurück zum Zitat Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61: 559–68PubMedCrossRef Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61: 559–68PubMedCrossRef
22.
Zurück zum Zitat Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160(7): 1277–85PubMedCrossRef Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160(7): 1277–85PubMedCrossRef
23.
Zurück zum Zitat Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995; 7: 89–104PubMedCrossRef Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995; 7: 89–104PubMedCrossRef
24.
Zurück zum Zitat Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994; 9: 245–50PubMedCrossRef Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994; 9: 245–50PubMedCrossRef
25.
Zurück zum Zitat Reynolds III CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry 1996; 153: 1288–92PubMed Reynolds III CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry 1996; 153: 1288–92PubMed
26.
Zurück zum Zitat Alexopoulos GS, Meyers BS, Young RC, et al. Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53: 305–12PubMedCrossRef Alexopoulos GS, Meyers BS, Young RC, et al. Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53: 305–12PubMedCrossRef
27.
Zurück zum Zitat Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevent Treat 2002; 5: Article 23, Epub 2002 Jul 15 Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevent Treat 2002; 5: Article 23, Epub 2002 Jul 15
28.
Zurück zum Zitat Miller FE. Strategies for the rapid treatment of depression. Hum Psychopharmacol 2001; 16: 125–32PubMedCrossRef Miller FE. Strategies for the rapid treatment of depression. Hum Psychopharmacol 2001; 16: 125–32PubMedCrossRef
29.
Zurück zum Zitat Flint AJ, Rifat SL. Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5: 103–7PubMedCrossRef Flint AJ, Rifat SL. Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5: 103–7PubMedCrossRef
30.
Zurück zum Zitat Karp JF, Frank E, Anderson B, et al. Time to remission in late-life depression: analysis of effects of demographic, treatment, and life-events measures. Depression 1993; 1: 250–6CrossRef Karp JF, Frank E, Anderson B, et al. Time to remission in late-life depression: analysis of effects of demographic, treatment, and life-events measures. Depression 1993; 1: 250–6CrossRef
31.
Zurück zum Zitat Dew MA, Reynolds III CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016–24PubMedCrossRef Dew MA, Reynolds III CF, Houck PR, et al. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016–24PubMedCrossRef
32.
Zurück zum Zitat Gildengers AG, Houck PR, Mulsant BH, et al. Course and rate of antidepressant response in the very old. J Affect Disord 2002; 69: 177–84PubMedCrossRef Gildengers AG, Houck PR, Mulsant BH, et al. Course and rate of antidepressant response in the very old. J Affect Disord 2002; 69: 177–84PubMedCrossRef
33.
Zurück zum Zitat Reynolds III CF, Frank E, Dew MA, et al. Treatment of 70(+)-year-olds with recurrent major depression. Am J Geriatr Psychiatry 1999; 7: 64–9PubMed Reynolds III CF, Frank E, Dew MA, et al. Treatment of 70(+)-year-olds with recurrent major depression. Am J Geriatr Psychiatry 1999; 7: 64–9PubMed
34.
Zurück zum Zitat Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989; 28: 1–9PubMedCrossRef Georgotas A, McCue RE, Cooper TB, et al. Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine. Psychiatry Res 1989; 28: 1–9PubMedCrossRef
35.
Zurück zum Zitat Gildengers AG, Houck PR, Mulsant BH, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharm. In press Gildengers AG, Houck PR, Mulsant BH, et al. Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. J Clin Psychopharm. In press
36.
Zurück zum Zitat Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002; 59: 729–35PubMedCrossRef Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002; 59: 729–35PubMedCrossRef
37.
Zurück zum Zitat Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord 2003 Apr; 74(2): 191–5PubMedCrossRef Birkenhager TK, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord 2003 Apr; 74(2): 191–5PubMedCrossRef
38.
Zurück zum Zitat Reynolds III CF, Dew MA, Frank E, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155: 795–9PubMed Reynolds III CF, Dew MA, Frank E, et al. Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155: 795–9PubMed
39.
Zurück zum Zitat Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60: 610–7PubMedCrossRef Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60: 610–7PubMedCrossRef
40.
Zurück zum Zitat Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717–26PubMedCrossRef Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 1998; 13: 717–26PubMedCrossRef
41.
Zurück zum Zitat Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000; 157: 722–8PubMedCrossRef Lenze EJ, Mulsant BH, Shear MK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000; 157: 722–8PubMedCrossRef
42.
Zurück zum Zitat Lenze EJ, Mulsant BH, Shear MK, et al. Anxiety symptoms in elderly patients with depression: what is the best approach to treatment? Drugs Aging 2002; 19: 753–60PubMedCrossRef Lenze EJ, Mulsant BH, Shear MK, et al. Anxiety symptoms in elderly patients with depression: what is the best approach to treatment? Drugs Aging 2002; 19: 753–60PubMedCrossRef
43.
Zurück zum Zitat Mulsant BH, Reynolds CF, Shear MK, et al. Comorbid anxiety disorders in late-life depression. Anxiety 1996; 2: 242–7PubMedCrossRef Mulsant BH, Reynolds CF, Shear MK, et al. Comorbid anxiety disorders in late-life depression. Anxiety 1996; 2: 242–7PubMedCrossRef
44.
Zurück zum Zitat Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003; 77(3): 247–54PubMedCrossRef Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003; 77(3): 247–54PubMedCrossRef
45.
Zurück zum Zitat Grunhaus L, Rabin D, Greden JF. Simultaneous panic and depressive disorder: response to antidepressant treatments. J Clin Psychiatry 1986; 47: 4–7PubMed Grunhaus L, Rabin D, Greden JF. Simultaneous panic and depressive disorder: response to antidepressant treatments. J Clin Psychiatry 1986; 47: 4–7PubMed
46.
Zurück zum Zitat Arve S, Tilvis RS, Lehtonen A, et al. Coexistence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging 1999; 11: 90–5PubMed Arve S, Tilvis RS, Lehtonen A, et al. Coexistence of lowered mood and cognitive impairment of elderly people in five birth cohorts. Aging 1999; 11: 90–5PubMed
47.
Zurück zum Zitat Magni G, Palazzolo O, Bianchin G. The course of depression in elderly outpatients. Can J Psychiatry 1988; 33: 21–4PubMed Magni G, Palazzolo O, Bianchin G. The course of depression in elderly outpatients. Can J Psychiatry 1988; 33: 21–4PubMed
48.
Zurück zum Zitat Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56: 713–8PubMedCrossRef Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56: 713–8PubMedCrossRef
49.
Zurück zum Zitat Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57: 285–90PubMedCrossRef Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000; 57: 285–90PubMedCrossRef
50.
Zurück zum Zitat Agbayewa MO. Outcome of depression in a geriatric medical day hospital following psychiatric consultation. Int J Geriatr Psychiatry 1990; 5: 33–9CrossRef Agbayewa MO. Outcome of depression in a geriatric medical day hospital following psychiatric consultation. Int J Geriatr Psychiatry 1990; 5: 33–9CrossRef
51.
Zurück zum Zitat Burvill PW, Hall WD, Stampfer HG, et al. The prognosis of depression in old age. Br J Psychiatry 1991; 158: 64–71PubMedCrossRef Burvill PW, Hall WD, Stampfer HG, et al. The prognosis of depression in old age. Br J Psychiatry 1991; 158: 64–71PubMedCrossRef
52.
Zurück zum Zitat Baldwin RC, Benbow SM, Mariott A, et al. Depression in old age: a reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 1993; 163: 82–90PubMedCrossRef Baldwin RC, Benbow SM, Mariott A, et al. Depression in old age: a reconsideration of cerebral disease in relation to outcome. Br J Psychiatry 1993; 163: 82–90PubMedCrossRef
53.
Zurück zum Zitat Knowles JB, MacLean AW. Age-related changes in sleep in depressed and healthy subjects: a meta-analysis. Neuropsychopharm 1990; 3: 251–9 Knowles JB, MacLean AW. Age-related changes in sleep in depressed and healthy subjects: a meta-analysis. Neuropsychopharm 1990; 3: 251–9
54.
Zurück zum Zitat Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–90PubMedCrossRef Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–90PubMedCrossRef
55.
Zurück zum Zitat Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9PubMedCrossRef Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9PubMedCrossRef
56.
Zurück zum Zitat Small GW, Hamilton SH, Bystritsky A, et al. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7 Suppl.: 41–53PubMedCrossRef Small GW, Hamilton SH, Bystritsky A, et al. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7 Suppl.: 41–53PubMedCrossRef
57.
Zurück zum Zitat Salloway S, Boyle PA, Correia S, et al. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Am J Geriatr Psychiatry 2002; 10: 107–11PubMed Salloway S, Boyle PA, Correia S, et al. The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Am J Geriatr Psychiatry 2002; 10: 107–11PubMed
58.
Zurück zum Zitat Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998; 28: 1015–26PubMedCrossRef Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 1998; 28: 1015–26PubMedCrossRef
59.
Zurück zum Zitat Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995; 37: 151–60PubMedCrossRef Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995; 37: 151–60PubMedCrossRef
60.
Zurück zum Zitat Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry 2002; 10: 592–8PubMed Miller MD, Lenze EJ, Dew MA, et al. Effect of cerebrovascular risk factors on depression treatment outcome in later life. Am J Geriatr Psychiatry 2002; 10: 592–8PubMed
61.
Zurück zum Zitat Mulder RT. Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002; 159: 359–71PubMedCrossRef Mulder RT. Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002; 159: 359–71PubMedCrossRef
62.
Zurück zum Zitat Reynolds III CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281: 39–45PubMedCrossRef Reynolds III CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281: 39–45PubMedCrossRef
63.
Zurück zum Zitat Dew MA, Reynolds CF, Mulsant BH, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord 2001; 65: 155–66PubMedCrossRef Dew MA, Reynolds CF, Mulsant BH, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord 2001; 65: 155–66PubMedCrossRef
64.
Zurück zum Zitat Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782–6PubMedCrossRef Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782–6PubMedCrossRef
65.
Zurück zum Zitat Quitkin FM, Rabkin JG, Markowitz JM, et al. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987; 44: 259–64PubMedCrossRef Quitkin FM, Rabkin JG, Markowitz JM, et al. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987; 44: 259–64PubMedCrossRef
66.
Zurück zum Zitat Pinder RM. Depression: the relevance of the time factor. J Clin Psychiatry 2001; 62(15 Suppl.): 5–7PubMed Pinder RM. Depression: the relevance of the time factor. J Clin Psychiatry 2001; 62(15 Suppl.): 5–7PubMed
67.
Zurück zum Zitat Parker G, Roy K, Menkes DB, et al. How long does it take for antidepressant therapies to act? Aust N Z J Psychiatry 2000; 34: 65–70PubMedCrossRef Parker G, Roy K, Menkes DB, et al. How long does it take for antidepressant therapies to act? Aust N Z J Psychiatry 2000; 34: 65–70PubMedCrossRef
68.
Zurück zum Zitat Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127–35PubMedCrossRef Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993; 3: 127–35PubMedCrossRef
69.
Zurück zum Zitat Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–22PubMedCrossRef Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–22PubMedCrossRef
70.
Zurück zum Zitat Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 1980; 137: 963–5PubMed Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry 1980; 137: 963–5PubMed
71.
Zurück zum Zitat Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152: 929–31PubMed Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152: 929–31PubMed
72.
Zurück zum Zitat Kaufmann MW, Cassem NH, Murray GB, et al. The use of methylphenidate in depressed patients after cardiac surgery. J Clin Psychiatry 1984; 45: 82–4PubMed Kaufmann MW, Cassem NH, Murray GB, et al. The use of methylphenidate in depressed patients after cardiac surgery. J Clin Psychiatry 1984; 45: 82–4PubMed
73.
Zurück zum Zitat Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9: 298–303PubMed Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001; 9: 298–303PubMed
74.
Zurück zum Zitat Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychpharmacol 2003; 13: 57–66CrossRef Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychpharmacol 2003; 13: 57–66CrossRef
75.
Zurück zum Zitat Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000; 12(1 Suppl.): 63–8PubMedCrossRef Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000; 12(1 Suppl.): 63–8PubMedCrossRef
76.
Zurück zum Zitat Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ‘vascular depression’. Int J Geriatr Psychiatry 2001; 16: 254–60PubMedCrossRef Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of ‘vascular depression’. Int J Geriatr Psychiatry 2001; 16: 254–60PubMedCrossRef
77.
Zurück zum Zitat Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry 1997; 54: 915–22PubMedCrossRef Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry 1997; 54: 915–22PubMedCrossRef
78.
Zurück zum Zitat Green TD, Reynolds III CF, Mulsant BH, et al. Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. J Geriatr Psychiatry Neurol 1999; 12: 67–71PubMedCrossRef Green TD, Reynolds III CF, Mulsant BH, et al. Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. J Geriatr Psychiatry Neurol 1999; 12: 67–71PubMedCrossRef
79.
Zurück zum Zitat Smith GS, Reynolds III CF, Houck PR, et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 2002; 10: 561–7PubMed Smith GS, Reynolds III CF, Houck PR, et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry 2002; 10: 561–7PubMed
80.
Zurück zum Zitat Reynolds III CF. Effects of therapeutic sleep deprivation on speed of antidepressant response in elderly depressed patients. Annual Meeting of the American Association of Geriatric Psychiatry; 2003 Mar 3–5, Honolulu Reynolds III CF. Effects of therapeutic sleep deprivation on speed of antidepressant response in elderly depressed patients. Annual Meeting of the American Association of Geriatric Psychiatry; 2003 Mar 3–5, Honolulu
81.
Zurück zum Zitat Sumaya IC, Rienzi BM, Deegan II JF, et al. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. J Gerontol Biol Sci Med Sci 2001; 56: M356–60CrossRef Sumaya IC, Rienzi BM, Deegan II JF, et al. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. J Gerontol Biol Sci Med Sci 2001; 56: M356–60CrossRef
82.
Zurück zum Zitat Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry 2003; 64: 648–53PubMedCrossRef Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry 2003; 64: 648–53PubMedCrossRef
83.
Zurück zum Zitat Kobak KA, Greist JH, Jefferson JW, et al. New technologies to improve clinical trials. J Clin Psychopharmacol 2001; 21: 255–6PubMedCrossRef Kobak KA, Greist JH, Jefferson JW, et al. New technologies to improve clinical trials. J Clin Psychopharmacol 2001; 21: 255–6PubMedCrossRef
Metadaten
Titel
Time Course of Response to Antidepressants in Late-Life Major Depression
Therapeutic Implications
verfasst von
Ellen M. Whyte
Dr Mary Amanda Dew
Ariel Gildengers
Eric J. Lenze
Ashok Bharucha
Benoit H. Mulsant
Charles F. Reynolds III
Publikationsdatum
01.07.2004
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 8/2004
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421080-00004

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.